Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085644
Status:
COMPLETED
Last Update Posted:
2011-04-21
First Post:
2004-06-10
Brief Title:
Human Anti-tumor Necrosis Factor TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATLAS
Brief Summary:
The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week eow in subjects with active ankylosing spondylitis AS who have had an inadequate response to or who are intolerant to treatment with at least 1 nonsteroidal anti-inflammatory drug NSAID and who may have also failed treatment with at least 1 disease-modifying antirheumatic drug DMARD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None